Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C

British Journal of Psychiatry

Volumn 206, Issue 1, 2015, Pages 45-51

  Sarkar, Susanne ^a,b   Sarkar, Rahul ^c   Berg, Thomas ^d   Schaefer, Martin ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Asklepios Westklinikum Hamburg   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SADNESS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; HEPATITIS C, CHRONIC; MULTICENTER STUDY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANTIVIRAL AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MILD COGNITIVE IMPAIRMENT; RISK FACTORS;

EID: 84920365560     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.141770     Document Type: Article

References (39)

1. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-76.
2. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 731-46.
3. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-90.
4. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991-8.
5. Sarkar S, Schafer M. Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta analysis. Psychosomatics 2014; 55: 221-34.
6. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157: 94-103.
7. Gumnick JK, Nemeroff, CB. Problems with currently available antidepressants. J Clin Psychiatry 2000, 61 (suppl 10): 5-15.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV). APA, 1994.
9. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20): 22-33.
10. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press, 1996.
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4: 561-71.
13. Zimmerman M, Posternak MA, Chelminski I. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 2004; 19: 215-20.
14. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation. Neuropsychological Press, 1985.
15. Aschenbrenner S, Tucha O, Lange KW. Regensburger Wortflüssigkeits-test (RWT). Hogrefe Verlag, 2000.
16. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment - Geriatric (SCAG). J Am Geriatr Soc 1974; 22: 107-113
17. Schafer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007; 16: 186-201.
18. Jiang HY, Deng M, Zhang YH, Chen HZ, Chen Q, Ruan B. Specific serotonin reuptake inhibitors prevent interferon-a-induced depression in patients with hepatitis C: a meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 1452-60.
19. Capuron L, Ravaud A. Prediciton of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340: 1370.
20. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004; 18: 205-13.
21. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120.
22. Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression (SSD): a new mood disorder? J Clin Psychiatry 1994; 55: 18-28.
23. Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996; 153: 1411-7.
24. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depression. J Affect Disord 1997; 45: 5-17.
25. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998; 55: 694-700.
26. Broadhead WE, Blazer DG, George LK, Tse LK. Depression, disability days and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524-8.
27. Howarth E, Johnson J, Klerman GL, Weissmann MM. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992; 49: 817-23.
28. Sherbourne CD, Wells KB, Hays RD, Rogers W, Burnam MA, Judd LL. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. Am J Psychiatry 1994; 151: 1777-84.
29. Kraus MR, Schafer A, Schoettker K, Keicher C, Weissbruch B, Hofbrauer I, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
30. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006; 145: 39-48.
31. Tillmann HL, Wiese M, Braun Y, Wiegand J, Tenckhoff S, Mössner J, et al. Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepat 2011; 18: 252-61.
32. Forton DM, Hamilton G, Allsop JM, Grover VP, Wesnes K, O'Sullivan C, et al. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol 2008; 49: 316-22.
33. Senzolo M, Schiff S, D'Aloiso CM, Crivellin C, Cholongitas E, Burra P, et al. Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 2011; 17: 3369-74.
34. Abrantes J, Torres DS, de Mello CE. Patients with hepatitis C infection and normal liver function: an evaluation of cognitive function. Postgrad Med J 2013; 89: 433-9.
35. McDermott LM, Ebmeir KP. A meta-analysis of depression severity and cognitive function. J Affect Disord 2009; 119: 1-8.
36. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 2012; 28: 1-52.
37. Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. Am J Geriatr Psychiatry 2002; 10: 687-95.
38. Negro F, Clément S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009; 16: 681-8.
39. Rivero-Juarez A, Mira JA, Camacho A, Neukam K, Perez-Camacho I, Caruz A, et al. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Infection 2013; 41: 21-6.